spacer
home > white papers > Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler
WHITE PAPERS

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Backward Thinking The Reverse Engineering of A Pressurized Metered Dose Inhaler By: Sarah Dexter & Alex Slowey, 3M Drug Delivery Systems Introduction Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.

Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.

The development of generic pMDIs must therefore use a total system approach to fully design and optimize new products to be safe, efficacious, robust and reliable during patient use and over the product shelf life. In order to develop a generic equivalent, a number of elements are required to work together to ensure that the finished pMDIs operate appropriately and meet the appropriate regulatory and quality requirements. These sub-systems can be summarized as the input active pharmaceutical ingredient (API), formulation composition, actuator, valve, canister and the secondary packaging.

Although significant information can be obtained from an in-vitro perspective, it is often the generation of in-vivo clinical data that is required to demonstrate equivalence between a new generic pMDI and the reference marketed product. In Europe, Orally Inhaled Product (OIP) guidelines describe a stepwise approach that should be employed to develop and gain registration of generic pMDI equivalents to current marketed products [1].

This article considers the various components of a reference marketed product that should be subject to reverse engineering and are described under the relevant headings below.

Understanding of these factors should be established in parallel to determining the pharmaceutical performance of the reference marketed product. Determination of the CQAs should include assessing the emitted dose of the product via dose content uniformity (DCU) or Uniformity of Delivered Dose (UoDD) analysis depending on the target market. The aerodynamic particle size distribution (APSD) of the emitted dose should also be established using appropriate methodology (for example Andersen Cascade Impactor (ACI) or Next Generation Impactor (NGI)). Analytical methodology for determining such factors should be appropriately developed and validated for this purpose. Testing regimens must be developed with consideration to both the marketed product and development products to ensure no bias in testing.

When selecting reference marketed products for reverse engineering, consider that products supplied by the same manufacturer to different markets may not be identical. Some differing product attributes may be obvious such as the presence of a dose counter and particular secondary packaging, while others are subtler and are only discernable with close internal inspection. Product differences may also exist between different product strengths.

Formulation

Formulation Composition

API concentration(s) should be discernible from the reference marketed product information whereas additional excipients should be listed in the published Summaries of Product Characteristics (SPCs) but are unlikely to specify a concentration or reason for inclusion. Information on additional excipient concentrations may be present in patents, clinical literature or other sources such as the FDA Inactive Ingredients website. A thorough review of the patent landscape is advised, not only to ascertain if a direct copy is feasible but also to understand the Intellectual Property (IP) and freedom to practice surrounding the manufacture/processing of the API or the pMDI product.

Visual examination of the formulation will determine whether the reference marketed product is a solution or a suspension and may offer insights into formulation composition and its suspension characteristics. Observing suspension behavior (for example, the rate of creaming or sedimentation) may be useful for optimizing analytical methodology and developing patient usage instructions. Visualizing formulation suspension characteristics and deposition on the container closure system (CCS) may help to explain any trends in pharmaceutical performance data.

API Particle Size Distribution (Suspension only)

Identifying the particle size distribution (PSD) of the API in the reference marketed product enables selection of suitable raw input materials for feasibility studies. This can be determined using appropriate laser diffraction particle sizing methodology, although it should be noted that this is particularly beneficial for pMDIs containing a single API, having limitations for a pMDI containing 2 or more APIs in suspension. For suspension products, selecting API with a PSD close to that of the marketed product increases the likelihood of matching the invitro APSD.

Fill Weight and Number of Actuations

Confirming fill weight and number of actuations per unit provides an indication of required canister size and amount of formulation overage in the canister. Differences in fill weight or canister size between the reference marketed product and generic product may lead to variances in headspace, which can impact pharmaceutical performance.

Actuator

During reverse engineering, the reference marketed product actuator is evaluated for key parameters such as mouthpiece design, spray cone, exit orifice attributes and expansion chamber geometry. These parameters should be incorporated into the design of the actuator for the new generic product if possible.

Actuator Features and Outer dimensions

Differences in actuator design and mouthpiece geometry will effect factors such as spray pattern, spray force and deposition of API on the actuator. The following general attributes should be considered:

 - Mouthpiece shape and actuator dimensions
 - Presence of dust cap (tethered or loose)
 - Materials of construction Other specific details that the developer should understand to aid the development of a generic equivalent product include:

1. Spacer Compatibility

Testing with a spacer may be required during pharmaceutical/clinical testing. Ensuring that the generic product is compatible with the specified spacer will improve the probability of matching the reference marketed product from an invitro and in-vivo perspective.

2. Dose Counter

Depending on the intended market, it is likely that some generic new pMDI products will require a dose counter or dose indicator (DC/DI). While it is unlikely that a direct copy of a dose counter will be possible, something functionally and visually similar should be developed in order to maintain patient recognition. The presence of a DC/DI (particularly integrated) may also impact the pharmaceutical performance of a product.

3. Spray Orifice Diameter (Exit Orifice Diameter)

The size of the spray orifice impacts the APSD of the formulation and is therefore a critical parameter when trying to match a reference marketed product. Typical spray orifice diameters range from 0.3 to 0.6 mm and can be determined using microscopy.

Generally, the smaller the spray orifice diameter, the finer the spray, which leads to lower API throat deposition and a greater Fine Particle Mass (FPM). However, this may also lead to greater mouthpiece deposition and an increased risk of actuator occlusion.

The quality of the spray orifice finish is also important as a poor quality finish may impact the alignment of the spray leading to increased API deposition on the actuator and an altered APSD profile.

4. Spray Pattern and Plume Geometry

Spray pattern and plume geometry are important tests for assessing the performance of the actuator and can be affected by various factors including the size, shape, and design of the actuator, the size of the valve metering chamber and side pierce, canister vapor pressure and formulation composition. The data from the reference marketed product provides a baseline for screening hardware and formulation options.

5. Spray Force

The force of the emitted spray is closely related to throat deposition. Spray force measurement of the reference marketed product will provide a reference that should not be exceeded to ensure similar deposition profiles and patient perception of the new generic pMDI product. It has therefore been suggested that impaction force may provide a better way to evaluate in-vitro equivalence in support of new drug applications (NDAs) or abbreviated new drug applications (ANDAs) for orally inhaled drug products. The belief is that it is more closely related to patient sensation and aerosol deposition than the current parameters [2].

Container Closure System

Valve

A clear understanding of the exact composition and functionality of the reference marketed product’s valve allows for selection of an appropriate valve for the generic pMDI product. Differences may affect factors such as formulation compatibility and pharmaceutical performance.

Many valve attributes of a reference marketed product need to be considered prior to generic product development such as the metering volume, the manufacturer and the materials of construction and any unusual features of the valve which may need to be understood.

Valve metering volume may be determined from information stated in the SPC or prescribing information. Confirming valve volume through laboratory testing enables selection of the correctly sized valve metering chamber to match the reference marketed product and highlights any differences between different product strengths.

Canister

Information on the canister and or coating may be listed in the SPC or prescribing information. The presence of a coating on the canister may indicate deposition issues with the API or incompatibilities with the canister material. Identification of the coating is important if a direct match to the reference marketed product is required, otherwise confirmation of coating presence may be adequate. The height and width of the canister will determine its physical compatibility with various actuators and dose counters.

Secondary Packaging

Foil pouching and desiccant may impact product performance throughout the product’s shelf life. If present for the reference marketed product, they should be included in feasibility/development studies but they don’t necessarily have to match exactly.

Attributes to be considered when analyzing secondary packaging include:
 - Constitution of secondary packaging (for example, carton, desiccant, foil overwrap and PIL)
 - Purpose of the secondary packaging (this can be determined through appropriate studies).
 - If included, dimensions and composition of foil overwrap and quantity / type of desiccant

Conclusion

As this overview illustrates, development of generic pMDIs is a technically challenging process that requires significant expertise. The growing market trend towards lower cost generic products means that companies need experienced partners to develop robust generic pMDI products that meet the requirements of the current regulatory landscape. The most qualified partners will be those able to demonstrate significant experience formulating, developing and gaining successful registration of multiple pMDI products.

Being able to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the current reference marketed product through reverse engineering, in order to enable appropriate in-vitro test and reference product matching strategies to be adopted is therefore a key step in the successful generic pMDI product development process.

References
1. CPMP/EWP/4151/00 Rev. 1 (August 2009): CHMP Guideline on the Requirements for Clinical Documentation for Orally Inhaled Products (OIP) Including the Requirements for Demonstration of Therapeutic Equivalence Between Two Inhaled Products for use in the Treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in Adults and for use in the Treatment of Asthma in Children and Adolescents [OIP Guideline].
2. Changning Guo, Wei Ye, John Kauffman, William H Doub, Evaluation of Impaction Force of Nasal Sprays and Metered-Dose Inhalers Using the Texture Analyser☆, Journal of Pharmaceutical Sciences, Volume 98, Issue 8, August 2009, Pages 2799-2806, ISSN 0022-3549, http://dx.doi.org/10.1002/jps.21648.
Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Signant Health Proudly Sponsors “DISORDER: The Rare Disease Film Festival” to Raise Awareness and Hope for Millions of Families Worldwide

PHILADELPHIA, PA –September 30, 2019: There are 7,000 recognized rare disease conditions that affect between 25 and 30 million people in the United States alone, and the vast majority are totally unknown in the community. What if there was a film to bring each of these diseases, and the people fighting them, into the spotlight?
More info >>


White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>


Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement